Table 4.

One-way sensitivity analyses for sarcoma patients in France, all anthracycline doses

Description of analysis	No dexrazoxane		With dexrazoxane		Incremental costs €	Incremental QALYs	ICER €
	Total costs €	Total QALYs	Total costs €	Total QALYs
Base case	12,102	19.78	12,549	20.35	447	0.57	791
Risk of CHF is based on French general population prevalence data multiplied with relative risks for childhood cancer survivors [15]	18,047	15.22	15,437	17.61	− 2609	2.39	Dominant
Risk of CHF is extrapolated with a linear function	11,854	20.06	12,477	20.48	624	0.42	1493
Risk of death modelled with general population life tables multiplied by SMR for childhood cancer survivors [20]	13,103	19.70	13,668	20.17	565	0.47	1214
Treatment effect modelled with Bayesian RR	12,099	19.78	12,575	20.31	476	0.53	895
Utility data based on NYHA class [22] and not differentiated by age	12,099	20.37	12,548	20.61	449	0.23	1922

CHF congestive heart failure, ICER incremental cost effectiveness ratio, NYHA New York Heart Association, QALY quality-adjusted life years, RR relative risk, SMR standardised mortality ratio